These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1524 related articles for article (PubMed ID: 33560344)

  • 1. Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes.
    Wang J; Cooper JM; Gokhale K; Acosta-Mena D; Dhalla S; Byne N; Chandan JS; Anand A; Okoth K; Subramanian A; Bangash MN; Jackson T; Zemedikun D; Taverner T; Hanif W; Ghosh S; Narendran P; Toulis KA; Tahrani AA; Surenthirakumaran R; Adderley NJ; Haroon S; Khunti K; Sainsbury C; Thomas GN; Nirantharakumar K
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1255-1268. PubMed ID: 33560344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
    Khunti K; Knighton P; Zaccardi F; Bakhai C; Barron E; Holman N; Kar P; Meace C; Sattar N; Sharp S; Wareham NJ; Weaver A; Woch E; Young B; Valabhji J
    Lancet Diabetes Endocrinol; 2021 May; 9(5):293-303. PubMed ID: 33798464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19.
    Lalau JD; Al-Salameh A; Hadjadj S; Goronflot T; Wiernsperger N; Pichelin M; Allix I; Amadou C; Bourron O; Duriez T; Gautier JF; Dutour A; Gonfroy C; Gouet D; Joubert M; Julier I; Larger E; Marchand L; Marre M; Meyer L; Olivier F; Prevost G; Quiniou P; Raffaitin-Cardin C; Roussel R; Saulnier PJ; Seret-Begue D; Thivolet C; Vatier C; Desailloud R; Wargny M; Gourdy P; Cariou B;
    Diabetes Metab; 2021 Sep; 47(5):101216. PubMed ID: 33309936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus.
    Yen FS; Wang SI; Lin SY; Wei JC
    Diabetes Res Clin Pract; 2023 Jun; 200():110692. PubMed ID: 37156428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.
    Morgan CL; Poole CD; Evans M; Barnett AH; Jenkins-Jones S; Currie CJ
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4605-12. PubMed ID: 23076348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
    Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L
    Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study.
    Sainsbury C; Wang J; Gokhale K; Acosta-Mena D; Dhalla S; Byne N; Chandan JS; Anand A; Cooper J; Okoth K; Subramanian A; Bangash MN; Taverner T; Hanif W; Ghosh S; Narendran P; Cheng KK; Marshall T; Gkoutos G; Toulis K; Thomas N; Tahrani A; Adderley NJ; Haroon S; Nirantharakumar K
    Diabetes Obes Metab; 2021 Jan; 23(1):263-269. PubMed ID: 32991065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study.
    Bramante CT; Johnson SG; Garcia V; Evans MD; Harper J; Wilkins KJ; Huling JD; Mehta H; Alexander C; Tronieri J; Hong S; Kahkoska A; Alamgir J; Koraishy F; Hartman K; Yang K; Abrahamsen T; Stürmer T; Buse JB;
    PLoS One; 2022; 17(11):e0271574. PubMed ID: 36395143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design.
    Yen FS; Chen W; Wei JC; Hsu CC; Hwu CM
    PLoS One; 2018; 13(10):e0204859. PubMed ID: 30286138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? a multivariable and propensity score-adjusted meta-analysis.
    Ma Z; Krishnamurthy M
    PLoS One; 2023; 18(2):e0282210. PubMed ID: 36821577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study.
    Christiansen C; Johansen M; Christensen S; O'Brien JM; Tønnesen E; Sørensen H
    Crit Care; 2013 Sep; 17(5):R192. PubMed ID: 24018017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study.
    Jiang N; Chen Z; Liu L; Yin X; Yang H; Tan X; Wang J; Li H; Tian M; Lu Z; Xiong N; Gong Y
    Diabetes Res Clin Pract; 2021 Mar; 173():108619. PubMed ID: 33310173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan.
    Chang CH; Sakaguchi M; Dolin P
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1196-1203. PubMed ID: 27221971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study.
    Oh TK; Song IA
    Acta Diabetol; 2021 Jun; 58(6):771-778. PubMed ID: 33582839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?
    Do JY; Kim SW; Park JW; Cho KH; Kang SH
    Diabetes Metab; 2021 Jul; 47(4):101208. PubMed ID: 33160030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.